Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Receivables: 2013-2025

Historic Change in Receivables for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to $356,000.

  • Ocular Therapeutix's Change in Receivables rose 11766.67% to $356,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $533,000, marking a year-over-year decrease of 91.98%. This contributed to the annual value of $6.2 million for FY2024, which is 27.92% up from last year.
  • According to the latest figures from Q3 2025, Ocular Therapeutix's Change in Receivables is $356,000, which was down 93.14% from $5.2 million recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's Change in Receivables registered a high of $6.2 million during Q2 2023, and its lowest value of -$7.2 million during Q1 2025.
  • Its 3-year average for Change in Receivables is $858,455, with a median of $367,000 in 2024.
  • Data for Ocular Therapeutix's Change in Receivables shows a peak YoY increase of 11,766.67% (in 2025) and a maximum YoY decrease of 2,052.86% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Ocular Therapeutix's Change in Receivables stood at $1.6 million in 2021, then decreased by 3.79% to $1.5 million in 2022, then surged by 70.06% to $2.6 million in 2023, then dropped by 16.87% to $2.2 million in 2024, then skyrocketed by 11,766.67% to $356,000 in 2025.
  • Its last three reported values are $356,000 in Q3 2025, $5.2 million for Q2 2025, and -$7.2 million during Q1 2025.